Ken Griffin Xencor Inc Transaction History

Citadel Advisors LLC

$509 Billion
Q1 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Xencor Inc stock. As of the latest transaction made, Citadel Advisors LLC holds 2,200 shares of XNCR stock, worth $41,646. This represents 0.0% of its overall portfolio holdings.

Number of Shares

2,200

Previous 1,800 22.22%

Holding current value

$41,646

Previous $38,000 26.32%

% of portfolio

0.0%

Previous 0.0%

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$18.65 - $26.52 $2.77 Million - $3.94 Million	148,624 Added 87.7%	318,100 $7.04 Million
Q4 2023 Feb 14, 2024	BUY	$16.53 - $21.42 $2.33 Million - $3.02 Million	141,151 Added 498.33%	169,476 $3.6 Million
Q3 2023 Nov 14, 2023	SELL	$20.08 - $25.39 $1.43 Million - $1.81 Million	-71,392 Reduced 71.59%	28,325 $570,000
Q2 2023 Aug 14, 2023	SELL	$24.77 - $29.9 $1.81 Million - $2.18 Million	-72,986 Reduced 42.26%	99,717 $2.49 Million
Q1 2023 May 15, 2023	BUY	$25.95 - $36.95 $1.92 Million - $2.74 Million	74,075 Added 75.11%	172,703 $4.82 Million

Q4 2022 Feb 14, 2023	SELL	$24.79 - $30.86 $2.33 Million - $2.9 Million	-93,881 Reduced 48.77%	98,628 $2.57 Million
Q3 2022 Nov 14, 2022	BUY	$24.62 - $32.44 $2.59 Million - $3.41 Million	105,253 Added 120.63%	192,509 $5 Million
Q2 2022 Aug 15, 2022	BUY	$19.74 - $29.01 $1.33 Million - $1.95 Million	67,316 Added 337.59%	87,256 $2.39 Million
Q1 2022 May 16, 2022	SELL	$26.68 - $41.63 $799,332 - $1.25 Million	-29,960 Reduced 60.04%	19,940 $532,000
Q3 2021 Nov 15, 2021	BUY	$30.65 - $35.68 $219,791 - $255,861	7,171 Added 16.78%	49,900 $1.63 Million
Q2 2021 Aug 16, 2021	BUY	$34.33 - $44.68 $1.05 Million - $1.37 Million	30,673 Added 254.42%	42,729 $1.47 Million
Q1 2021 May 17, 2021	SELL	$40.81 - $53.88 $1.07 Million - $1.41 Million	-26,202 Reduced 68.49%	12,056 $519,000
Q4 2020 Feb 16, 2021	BUY	$36.63 - $47.63 $226,190 - $294,115	6,175 Added 19.25%	38,258 $1.67 Million
Q3 2020 Nov 16, 2020	SELL	$30.09 - $43.02 $645,159 - $922,391	-21,441 Reduced 40.06%	32,083 $1.24 Million
Q2 2020 Aug 14, 2020	SELL	$27.76 - $33.42 $1.66 Million - $2 Million	-59,817 Reduced 52.78%	53,524 $1.73 Million
Q1 2020 May 15, 2020	BUY	$20.69 - $37.79 $2.19 Million - $4 Million	105,961 Added 1435.79%	113,341 $3.39 Million
Q4 2019 Feb 14, 2020	SELL	$32.75 - $41.43 $1.2 Million - $1.51 Million	-36,536 Reduced 83.2%	7,380 $254,000
Q2 2019 Aug 14, 2019	BUY	$29.6 - $40.93 $242,808 - $335,748	8,203 Added 22.97%	43,916 $1.8 Million
Q1 2019 May 15, 2019	BUY	$27.85 - $38.09 $504,447 - $689,924	18,113 Added 102.91%	35,713 $0
Q2 2018 Aug 10, 2018	SELL	$28.41 - $42.41 $1.3 Million - $1.94 Million	-45,743 Reduced 72.21%	17,600 $0
Q1 2018 May 11, 2018	BUY	$21.18 - $33.78 $1.34 Million - $2.14 Million	63,343 New	63,343 $1.9 Million

Others Institutions Holding XNCR

# of Institutions

203

Shares Held

64M

Call Options Held

2.2K

Put Options Held

1.3K

View Full List

About Xencor Inc

Ticker XNCR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,698,100
Market Cap $1.13B
Description
Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal ...

More about XNCR

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account